SAN FRANCISCO — Pharmaceutical company Medivation Inc. and the UC Regents are gearing up for another round in a bitter dispute over the building blocks of a successful prostate cancer medication.

Medivation, which helped fund research conducted at UCLA, filed a complaint in 2011 accusing the researchers and the UC Regents of hiding promising discoveries. That case concluded last year with a limited win for Medivation and a $400,000 award in the company’s favor.